Industries Served — Biotech
Biotech Marketing & Commercial Growth
Strategic marketing consulting for biotech CEOs who need their commercial investment to drive measurable pipeline, partnerships, and revenue.
The Situation
Your Science Is Strong. Your Commercial Engine Is Not.
You have compelling data. The mechanism of action is differentiated. Your clinical results are promising or proven. The team has deep scientific expertise.
But commercial traction is not where it should be. Partnership discussions stall or produce underwhelming terms. Investor conversations require constant education before you can discuss valuation. Payer engagement is an afterthought when it should be shaping your development strategy. If you have a product in market, sales cycles stretch longer than your burn rate can tolerate, and market access remains a persistent challenge.
This is not a science problem. This is a commercial architecture problem.
Biotech companies face commercial challenges that compound at every stage. Pre-commercial companies struggle to position their science in ways that resonate with partners, investors, and future payers. Commercial-stage companies find that regulatory approval was only the beginning, and that market access, payer negotiations, and provider adoption require capabilities they never built.
The biotechs winning in this environment are not simply hiring commercial leadership late in the game. They are building commercial thinking into their strategy from early development, creating positioning that resonates across stakeholder types, and developing the market access and launch infrastructure that converts scientific innovation into commercial success.
The Real Barriers
Four Commercial Challenges to Biotech Growth — Most Face Several at Once
01
Positioning That Does Not Resonate Beyond Scientists
Your scientific narrative is rigorous and accurate. It also fails to connect with the audiences who will determine your commercial success. Investors want to understand market opportunity and competitive differentiation in business terms. Potential partners want clarity on strategic fit and commercial potential. Payers want to understand health economic value. Providers want to understand clinical utility in their practice context. You have one story when you need five.
02
Partnership Development That Underperforms
You need partnerships to scale, whether for development funding, manufacturing, distribution, or commercialization. But partnership discussions move slowly, produce disappointing terms, or fail entirely. Your outreach lacks the targeting precision and value proposition clarity that would attract the right partners and accelerate negotiations.
03
Market Access Strategy That Lags Development
Reimbursement strategy is treated as a late-stage problem when it should inform development decisions. You reach approval without the health economics evidence, payer engagement history, or pricing strategy that market access requires. Launch timelines slip while you scramble to build what should have been constructed years earlier.
04
Commercial Launch That Underperforms Projections
You achieved regulatory approval. The launch generated initial excitement. But adoption is slower than modeled. Payer coverage is narrower than expected. Providers are not prescribing at anticipated rates. The commercial infrastructure that seemed adequate is straining under real-world demands.
Our Approach
A Commercial Growth Approach Built for Biotech Realities
Novastrat Growth works with biotech CEOs to build commercial systems that create stakeholder alignment, accelerate partnership development, enable market access, and drive adoption.
We developed the MAPS Framework specifically to address the interconnected commercial challenges that biotech companies face. MAPS provides a structured approach to aligning your commercial investment with measurable outcomes, whether you are pre-clinical, in development, or commercial stage.
Our Biotech Commercial Practice Focuses On
Where We Focus
01
Strategic Positioning and Key Stakeholder Messaging
Translation of scientific differentiation into commercial positioning that resonates across stakeholder types. We help you build the narrative architecture that connects your science to investor interest, partnership value, payer relevance, and provider adoption. Your story becomes a commercial asset, not just a scientific explanation.
02
Ideal Partner and Customer Profile Development
Rigorous analysis to define which partners, payers, and providers represent your highest probability, highest value opportunities. We examine strategic fit, capability alignment, competitive dynamics, and decision-making patterns to build targeting that focuses your commercial efforts on the relationships that will actually advance your business.
03
Partnership Development Strategy
Design of partnership outreach and engagement programs that attract the right partners with compelling value propositions. We help you identify partnership targets, develop tailored engagement approaches, create partnership-ready materials, and navigate negotiations toward terms that serve your strategic interests.
04
Investor Communication and Positioning
Development of investor-facing narratives and materials that communicate commercial potential alongside scientific merit. We help biotech leadership teams articulate market opportunity, competitive positioning, and commercial strategy in terms that resonate with healthcare investors and support valuation discussions.
05
Market Access and Payer Strategy
Early-stage development of reimbursement strategy, health economics evidence requirements, and payer engagement plans. We help you understand what payers will require, build the evidence generation into your development program, and engage payers early enough to shape coverage decisions rather than react to them.
06
Health Economics and Value Communication
Creation of health economic models, value dossiers, and payer communication tools that demonstrate the economic case for your product. We help you quantify value in terms payers understand and build the evidence base that supports pricing and reimbursement success.
07
Launch Strategy and Commercial Infrastructure
For commercial-stage biotechs, design of launch plans that connect regulatory approval to market adoption. We help you build the commercial capabilities, channel strategies, and provider engagement programs that translate approval into revenue.
08
Provider Engagement and Adoption Strategy
Development of provider-facing positioning, education programs, and engagement strategies that drive prescribing behavior. We help you understand provider decision-making in your therapeutic area and build the commercial approaches that create adoption.
09
Digital Marketing and Awareness Building
Strategy for building market awareness among target audiences through digital channels. We design approaches that establish scientific and commercial credibility, generate inbound interest from partners and investors, and support commercial efforts with audiences who already understand your differentiation.
10
Pipeline Optimization and Conversion Improvement
Analysis of your current partnership and commercial pipeline to identify where opportunities stall, why they stall, and what interventions will accelerate movement. We find the leverage points that will improve commercial performance across stakeholder types.
11
Lowering Customer Acquisition Cost
For commercial-stage biotechs, systematic reduction of acquisition cost through better targeting, higher conversion rates, and more efficient channel spend. We identify where your commercial dollars are wasted and redesign resource allocation to acquire customers at sustainable cost.
12
Increasing Customer Lifetime Value
Strategy for expanding revenue from existing customer relationships through deeper engagement, expanded indications, and stronger retention. We help you build the post-launch engagement model that maximizes the commercial potential of each customer relationship.
13
KPI Visibility and Agile Decision Making
Design of commercial dashboards and reporting structures that give leadership real-time visibility into partnership pipeline, market access progress, launch performance, and leading indicators. We help you build the measurement infrastructure that enables quick pivots when market signals change.
14
Market Analysis
Deep examination of market size, competitive dynamics, treatment paradigms, and adoption patterns in your therapeutic area. We provide the market intelligence foundation that informs positioning, partnership strategy, pricing, and commercial resource allocation.
15
Competitive Analysis
Rigorous assessment of competitor positioning, clinical differentiation, market access status, and commercial strategies. We identify competitive vulnerabilities, differentiation opportunities, and the specific battlegrounds where you can win. Your commercial team gains actionable intelligence for every competitive encounter.
16
Building a Brand
Development of brand positioning and identity that establishes your company and product as credible, differentiated players in your therapeutic area. We help biotechs build brands that resonate with investors, partners, payers, and providers, creating preference and recognition that supports commercial success.
17
Channel Optimization
Analysis and refinement of your commercial channel strategy to maximize reach and efficiency. Whether you commercialize directly, through partners, through specialty pharmacy, or through hybrid models, we help you optimize your approach and ensure your strategy aligns with your market access realities and growth objectives.
Fit
Who We Work With
Our biotech clients typically share several characteristics. We work directly with CEOs, often alongside Chief Commercial Officers, Chief Business Officers, or investors who recognize that commercial strategy requires the same rigor as scientific development.
Pre-commercial companies in Phase 2 or later seeking to build commercial strategy alongside development.
Commercial-stage companies with revenue between $10M and $200M facing launch challenges or growth plateaus.
VC-backed or public with growth expectations that current commercial performance or positioning is not meeting.
Science that is differentiated but commercial traction, partnership development, or market access that lags the opportunity.
The Novastrat Growth Engagement Model
A Structured Approach — Our MAPS Framework — That Moves Efficiently From Diagnosis to Strategy to Execution
Phase 1 — "Measure"
Commercial Diagnostic
A focused four-to-six week assessment of your current commercial positioning, partnership pipeline, market access readiness, and competitive dynamics. We identify the highest leverage opportunities and the specific barriers preventing you from capturing them.
Phase 2 — "Assess and Prioritize"
Strategy Architecture
Development of a comprehensive commercial growth plan built on the MAPS Framework. This includes positioning and narrative architecture, partnership targeting and outreach strategy, market access planning, launch infrastructure design, and execution milestones. Any gaps in people, processes, or technology are identified. This becomes your working roadmap.
Phase 3 — "Scale" (optional)
Execution Partnership
For CEOs who want ongoing strategic support, we provide continued engagement to track progress, refine strategy as development milestones are reached or market feedback accumulates, and help navigate execution challenges as your commercial capabilities mature.
Not Sure Which Fits
Start a Conversation
If your biotech company has strong science but commercial positioning, partnership development, or market access that is not matching the opportunity, let's talk. A thirty-minute conversation will help us understand your situation and determine whether Novastrat Growth can add value.
FAQ
Frequently Asked Questions
How is Novastrat Growth different from biotech commercialization consultancies?
Large commercialization firms bring deep therapeutic expertise and significant bench strength. They also bring extended timelines, large teams, and methodologies designed for Big Pharma that don't always fit emerging biotech companies. We work as a small, senior team directly with CEOs, typically a single engagement lead through the entire relationship. Our focus is commercial marketing strategy and positioning, not regulatory consulting or clinical development.
When should a biotech company start thinking about commercial strategy?
Earlier than most do. Commercial considerations should inform development decisions starting in Phase 2, and sometimes earlier. Reimbursement strategy, competitive positioning, and market access planning take years to execute well. Companies that wait until Phase 3 or approval to build commercial capabilities consistently underperform at launch.
Do you work with pre-revenue biotech companies?
Yes. For pre-commercial companies, we focus on strategic positioning, partnership development, investor communication, and early market access planning. These are the commercial activities that create value before revenue exists and set the foundation for commercial success after approval.
How do you approach market access and payer strategy?
We help companies understand payer requirements and build evidence generation into development programs. This includes identifying the health economics data payers will require, designing evidence generation strategies, developing value communication tools, and building early payer engagement plans. For commercial-stage companies, we help optimize payer engagement and address coverage challenge messaging and narrative.
What is the MAPS Framework?
MAPS is our proprietary framework for diagnosing and addressing commercial growth challenges. It provides a structured approach to understanding where commercial performance is breaking down and what interventions will have the highest impact. You can explore the framework in detail on our MAPS Framework page.
How long does a typical engagement last?
The Commercial Diagnostic phase typically takes four to six weeks. Strategy Architecture requires an additional six to twelve weeks depending on complexity and stage. Many clients continue with Execution Partnership engagements as they progress through development milestones or navigate commercial launch.
What outcomes should I expect?
Specific outcomes depend on your stage and situation. Pre-commercial clients typically achieve differentiated positioning that resonates with partners and investors, partnership development strategies that accelerate deal flow, and market access plans that inform development decisions. Commercial-stage clients typically achieve improved launch performance, enhanced market access, and measurable improvement in revenue trajectory.
Do you work with investors on portfolio company commercial strategy?
Yes. We engage with venture capital and crossover investors on commercial strategy for portfolio companies, commercial due diligence for prospective investments, and post-investment commercial capability building.
How is biotech commercialization different from other healthcare sectors?
Biotech faces unique commercial challenges including longer development timelines that require early commercial planning, complex reimbursement environments that demand health economics evidence, specialty distribution channels that require specific capabilities, and provider audiences that require scientific credibility alongside commercial engagement. Success requires commercial approaches specifically designed for these realities.
Ready to Replace Random Acts of Marketing
With a System That Works?
Every engagement is scoped to your company, your stage, and your pace.
The first conversation is a fit check, not a pitch.